The company's synthetic Toll-like receptor 2 receptor agonists activate the innate immune system in the respiratory tract, preventing viral and bacterial dissemination to the lungs. Their products allow for topical delivery to the airways, targeting the primary site and preventing further complications in patients with pre-existing lung disease. Ena Respiratory is based in Melbourne, Australia, and is developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections, including COVID-19, rhinovirus, and influenza. The company has secured a Series A investment from Brandon Capital Partners, the Minderoo Foundation, and Uniseed, and has joined Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and BARDA. Ena Respiratory has also established a strategic partnership with the US COPD foundation and was awarded a USD4.38M grant from the United States Department of Defense to further support the development of INNA-051.